
Understand why TRT can improve anemia yet raise hematocrit, how clinicians use blood-count thresholds, and why monitoring matters.

Hematocrit is the share of blood volume made up of red blood cells. Testosterone replacement therapy (TRT) can increase it because testosterone stimulates red blood cell production. When that increase becomes excessive during treatment, clinicians call it erythrocytosis.
This article is for informational purposes and is not medical advice. A qualified clinician should interpret abnormal blood counts and assess anemia. Decisions about starting TRT or changing an existing treatment plan require individual medical care.
The Endocrine Society guidance described in this summary of hematocrit monitoring recommendations uses different thresholds before and during testosterone treatment. Those numbers answer different clinical questions. They are treatment decision points rather than a universal laboratory reference range for adult men.
Biologically, hematocrit describes how much of the blood's volume consists of red blood cells. It does not by itself explain why that proportion has changed or whether testosterone treatment is appropriate.
Before TRT begins, the guideline identifies hematocrit above 48% as a relative contraindication. For men at higher altitude, it uses above 50%. A relative contraindication means further evaluation is warranted rather than an automatic decision that treatment is impossible.
The distinction matters because a baseline result is not a treatment response. A high result before the first dose needs consideration on its own terms. It should not be interpreted using only the action threshold intended for someone already receiving testosterone.
During TRT, the guideline uses hematocrit above 54% as the threshold for action. Its recommendations include clinician-directed interruption of treatment and evaluation for hypoxia and sleep apnea. Decisions about subsequent treatment belong with the prescribing clinician.
The guideline also states that the hematocrit level at which cardiovascular or blood-vessel-blocking events become more likely is unknown. Such events were very uncommon in the randomized trials it reviewed among men who developed erythrocytosis. Therefore, 54% should not be presented as an exact biological boundary where harm suddenly begins.
The practical distinction is between a guideline action point and a precisely established risk boundary. The former gives clinicians a reason to reassess treatment. It does not establish the latter.
The Endocrine Society recommends checking hematocrit:
The guideline places these checks within a broader review of treatment response and adverse effects. Monitoring is not simply a search for a result above a cutoff. It also considers the blood count alongside the treatment's intended benefits.
For related context, understanding how the complete blood count contributes to TRT assessment helps place hematocrit within the wider laboratory discussion. The question is not just what the percentage says, but what it means in the course of care.
For adult men, the relevant clinical findings in this research are anemia and treatment-related erythrocytosis. The studies assess these through blood measurements. A symptom description should not be treated as a substitute for those measurements or for a clinician's assessment.
The Endocrine Society's approach also includes reviewing symptoms and treatment response. A rise in a blood marker is not enough on its own to establish that a man's overall condition has improved. Equally, a monitoring concern requires attention within the full treatment assessment.
Testosterone's effect on red blood cell production can be beneficial in some men with low testosterone and anemia. A published summary of a 2023 TRAVERSE analysis reports that anemia was corrected at 12 months in 45.0% of testosterone-treated men. The corresponding figure among placebo recipients was 33.9%.
That finding supports a potential benefit in the population studied. It also shows that anemia was not corrected in everyone who received testosterone. These findings are not a basis for treating anemia with testosterone alone.
The Endocrine Society's summary of the Testosterone Trials provides another view of the same trade-off. A greater proportion of older men with anemia assigned to testosterone had a hemoglobin increase of more than 1 g/dL than men assigned to placebo.
The guideline also reports that seven testosterone-treated men reached hemoglobin of at least 17.5 g/dL. None receiving placebo reached that level. The same treatment effect that improved a blood-count finding in some participants also produced high hemoglobin levels in others.
An excessive treatment-related hematocrit increase is described clinically as erythrocytosis. The guideline's trial review found it occurred more frequently with testosterone than with placebo. This is why an increase should not automatically be labeled a benefit simply because testosterone is expected to stimulate red blood cell production.
For someone reporting symptoms during TRT, the useful clinical discussion includes both treatment response and adverse effects. The blood count contributes to that discussion rather than replacing it. Our explanation of connecting symptoms with the wider hormone assessment addresses that distinction.
The guideline's meta-analysis was limited to transdermal treatment and studies lasting 12 to 52 weeks. Those results do not establish the same risk magnitude for every formulation or over longer periods.
For men 65 and older, the Endocrine Society recommends individualized decisions when suggestive symptoms or conditions accompany consistently low morning testosterone. It advises against routinely treating all older men with low testosterone. Potential anemia benefits belong within that individualized discussion rather than becoming a stand-alone reason for treatment.
The supported influences and clinical considerations here concern testosterone exposure and the circumstances surrounding the blood result. They should be separated from claims that a particular lifestyle change can reliably control a TRT-related rise.
Treatment formulation also matters when interpreting research. Because the guideline's reviewed studies were limited to transdermal treatment, those findings should not be used to assign an identical risk to every delivery method. A broader discussion of differences between testosterone delivery methods provides context without turning the comparison into a personal treatment recommendation.
The practical focus is a coordinated review of the baseline result and subsequent measurements. Treatment response and possible adverse effects remain part of that review. Neither a reassuring number nor an abnormal one should be treated as the complete assessment.
Ask: “How does my hematocrit compare with baseline and the relevant thresholds? Does any anemia need further evaluation? When should my next blood count be checked? How do the blood-count benefits and risks affect the assessment of my TRT?”
A red blood cell increase may help anemia yet create a monitoring concern, putting treatment benefit and follow-up needs in the same discussion. Testostra's evidence-led coverage puts TRT risks and monitoring in context so men can prepare informed questions without receiving a personal diagnosis or dosing plan.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.




Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra